Pharmaceuticals, Biotechnology and Life Sciences
– Exelixis has exclusive license to panel of monoclonal antibodies against an undisclosed oncology target for biologics applications, leveraging WuXi Biologics integrated technology platforms –
– In addition to a modest upfront payment, WuXi Biologic…
– Exelixis has exclusive license to panel of monoclonal antibodies against an undisclosed oncology target for biologics applications, leveraging WuXi Biologics integrated technology platforms –
– In addition to a modest upfront payment, WuXi Biologic…
− Technetium-99m is the daughter isotope of molybdenum-99 (Mo-99) –
− Collaboration enables integrating technology expertise to provide Tc-99m Generation Systems (TCM Generation Systems) that utilize non-uranium based Mo-99 produced using electron be…
Follows U.S. FDA acceptance of the Biologics License Application under Priority Review
Potential approval in Europe anticipated in early 2022
Significant commercial opportunity in Europe with projected peak revenue of $450M-$1.1B
CAMBRIDGE, Mass.–(…
Orphazyme Announces the Global Brand Name for Arimoclomol – MIPLYFFA – Ahead of Prospective FDA and EMA Approvals
Expanded its Early Access Program for NPC in the U.S. and Europe as Well as Expectation of European Regulatory Decision by Q4 2021
LOS A…
— Partnership with Parkinson Study Group Advisory Panel to collaborate on Parkinson’s Disease Program —
— Presentation at AD/PD™ 2021 Underscores Relevance of Cortexyme’s Approach —
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Cortexyme, Inc. (N…
DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C–(BUSINESS WIRE)–IQVIA™ (NYSE: IQV) announces that since September 2020 it has been collaborating with Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & J…
– Exelixis has exclusive license to panel of monoclonal antibodies against an undisclosed oncology target for biologics applications, leveraging WuXi Biologics integrated technology platforms –
– In addition to a modest upfront payment, WuXi Biologic…
First clinical trial of Aflibercept biosimilar to be completed in Korea
Supported by global formulation and process patents
DAEJEON, South Korea–(BUSINESS WIRE)–#196170KQ–Alteogen Inc. (KOSDAQ:196170) announced that it has completed Phase 1 …
First clinical trial of Aflibercept biosimilar to be completed in Korea
Supported by global formulation and process patents
DAEJEON, South Korea–(BUSINESS WIRE)–#196170KQ–Alteogen Inc. (KOSDAQ:196170) announced that it has completed Phase 1 …